



Announcement

NeuroSearch A/S – Share purchase programme – Status update

In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a share purchase programme under which the company will buy own shares for an amount of up to DKK 50 million during 2009.

The programme is structured according to European Commission Regulation No 2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules, for the purchase of own shares.

In the past week, since the issue of status announcement no. 45-09 of 7 September 2009, no transactions have been made under NeuroSearch’s share purchase programme.

NeuroSearch holds a total of 248,469 treasury shares of DKK 20 nominal value each, corresponding to 1.44% of the total number of 17,237,830 issued shares in NeuroSearch A/S.

An amount of DKK 22,510,369 remains to be used under the share purchase programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX Copenhagen on Friday 11 September 2009, this corresponds to a maximum of 154,180 additional NeuroSearch shares to be bought under the programme.

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations,
telephone: +45 4017 5103

About NeuroSearch – Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ OMX Copenhagen. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug pipeline comprises eight clinical (Phase I-III) development programmes: Huntexil™ (pridopidine) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson’s disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

